Key result
Moxonidine treatment for 12 weeks significantly decreased blood pressure, fasting glucose, triglycerides, total cholesterol, HOMA-IR, and albumin excretion, and increased serum adiponectin.
Why the study?
Does moxonidine improve adiponectin levels and metabolic parameters in non-diabetic women with essential hypertension?
Does moxonidine improve adiponectin levels and metabolic parameters in non-diabetic women with essential hypertension?
Moxonidine improves insulin resistance and increases adiponectin levels in non-diabetic hypertensive women, suggesting metabolic benefits beyond blood pressure lowering.
No takes yet. Share an insight, caveat, or question.
May support metabolic benefits beyond BP lowering in non-diabetic hypertensive women; leaves open confirmation in randomized trials.
Ebinç et al. (2008) studied Essential hypertension (n=108). Moxonidine vs. Normotensive women (baseline) / Pre-treatment baseline was evaluated on Lipid profile, insulin resistance, adiponectin levels, renal function and microalbuminuria. Moxonidine treatment for 12 weeks significantly decreased blood pressure, fasting glucose, triglycerides, total cholesterol, HOMA-IR, and albumin excretion, and increased serum adiponectin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: